XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Restatement of Previously Issued Financial Statements (Tables)
9 Months Ended
Sep. 30, 2023
Restatement of Previously Issued Financial Statements  
Summary of effect of the restatement on each financial statement line item

​

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Balance Sheet as of September 30, 2023 (Successor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Contingent consideration liability

 

$

74,505

​

$

6,656

​

(a)

​

$

81,161

Total liabilities

 

 

139,359

​

 

6,656

​

​

​

 

146,015

Additional paid-in capital

 

 

362,114

​

 

17,555

​

(a) (d) (e) (f)

​

 

379,669

Accumulated deficit

 

 

(423,148)

​

 

(24,211)

​

(a) (b) (c) (d) (e) (f)

​

 

(447,359)

Total AEON Biopharma, Inc. stockholders’ deficit

 

 

(121,740)

​

 

(6,656)

​

​

​

 

(128,396)

Total stockholders' deficit

 

 

(121,740)

​

 

(6,656)

​

​

​

 

(128,396)

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Selling, general and administrative

 

$

5,460

​

$

(195)

​

(d)

​

$

5,265

Research and development

 

 

6,383

​

 

5

​

(d)

​

 

6,388

Change in fair value of contingent consideration

 

 

(69,715)

​

 

(6,224)

​

(a)

​

 

(75,939)

Total operating costs and expenses

 

 

(57,872)

​

 

(6,414)

​

​

​

 

(64,286)

(Loss) income from operations

 

 

57,872

​

 

6,414

​

​

​

 

64,286

(Loss) income before taxes

 

 

43,875

​

 

6,414

​

​

​

 

50,289

(Loss) income and comprehensive (loss) income

 

 

43,875

​

 

6,414

​

​

​

 

50,289

Basic and diluted net (loss) income per share

 

$

1.19

​

$

0.16

​

​

​

$

1.35

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Change in fair value of convertible notes

 

$

2,582

​

$

(15,831)

​

(c)

​

$

(13,249)

Change in fair value of embedded forward purchase agreements and derivative liabilities

 

 

(4,959)

​

 

(6,830)

​

(b)

​

 

(11,789)

Total other (loss) income, net

 

 

(2,372)

​

 

(22,661)

​

​

​

 

(25,033)

(Loss) income before taxes

 

 

(5,000)

​

 

(22,661)

​

​

​

 

(27,661)

(Loss) income and comprehensive (loss) income

 

 

(5,000)

​

 

(22,661)

​

​

​

 

(27,661)

Basic and diluted net (loss) income per share

 

$

(0.04)

​

$

(0.16)

​

​

​

$

(0.20)

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Operations and Comprehensive loss for the period from January 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Change in fair value of convertible notes

 

$

(3,528)

​

$

(15,831)

​

(c)

​

$

(19,359)

Change in fair value of embedded forward purchase agreements and derivative liabilities

 

 

(4,959)

​

 

(6,830)

​

(b)

​

 

(11,789)

Total other (loss) income, net

 

 

(8,373)

​

 

(22,661)

​

​

​

 

(31,034)

(Loss) income before taxes

 

 

(38,017)

​

 

(22,661)

​

​

​

 

(60,678)

(Loss) income and comprehensive (loss) income

 

 

(38,017)

​

 

(22,661)

​

​

​

 

(60,678)

Basic and diluted net (loss) income per share

 

$

(0.28)

​

$

(0.16)

​

​

​

$

(0.44)

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Net loss

 

$

(5,000)

​

$

(22,661)

​

(b) (c)

​

$

(27,661)

Balance as of July 21, 2023 (Predecessor)

 

 

(288,159)

​

 

(22,661)

​

​

​

 

(310,820)

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from January 1, 2023 to July 21, 2023 (Predecessor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Net loss

 

$

(38,017)

​

$

(22,661)

​

(b) (c)

​

$

(60,678)

Balance as of July 21, 2023 (Predecessor)

 

 

(288,159)

​

 

(22,661)

​

​

​

 

(310,820)

​

​

​

​

​

​

​

​

​

​

​

​

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

​

As Reported

​

Adjustment

​

Reference

​

As Restated

Balance as of July 22, 2023 (Successor)

 

$

(167,976)

​

$

(12,880)

​

​

​

$

(180,856)

Net income

 

 

43,875

​

 

6,414

​

(a) (d)

​

 

50,289

Stock-based compensation expense

 

 

2,361

​

 

(190)

​

(d)

​

 

2,171

Balance as of September 30, 2023 (Successor)

 

 

(121,740)

​

 

(6,656)

​

​

​

 

(128,396)

​